BioSpace News Archive

Browse BioSpace’s published news and press releases by year, month, and day.
673 Results
Year
Month
Day
  • Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics.
  • Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body’s immune system to bring breakthrough treatments to patients.
  • Since 2006, Akron’s mission is to provide GMP-compliant materials and services that enable innovators to develop and commercialize advanced therapies. Along with its line of GMP quality cytokines, growth factors, blood-derived products, and custom media, Akron specializes in manufacturing custom plasmids and endonucleases to support viral vector and gene editing technologies.
  • Alto Neuroscience is redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines, helping patients get better faster.
  • ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases.
  • The Prelude Network (Prelude), the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in the U.S., is the clinic network of Inception - a company whose mission is to shift the paradigm of the fertility market by raising the standard of care, streamlining fragmented components into an integrated system and enhancing the overall patient experience.
  • Indalo Therapeutics is a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
  • Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications.
  • The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.
  • Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.